Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 36505470)

  • 1. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
    Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
    Lu Y; Liu H; Ye SG; Zhou LL; Luo X; Dang XY; Yuan XG; Qian WB; Liang AB; Li P
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):813-819. PubMed ID: 38049332
    [No Abstract]   [Full Text] [Related]  

  • 3. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
    Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
    Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
    Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
    Front Immunol; 2022; 13():969660. PubMed ID: 36059523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.
    Zhu W; Tao S; Miao W; Liu H; Yuan X
    Front Immunol; 2022; 13():894787. PubMed ID: 35757723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.
    Yang H; Xiang B; Song Y; Zhang H; Zhao W; Zou D; Lv F; Guo W; Liu A; Li C; Tan Z; Liu Y; Fu L; Guo H; Novotny W; Huang J; Li Y
    Blood Adv; 2022 Mar; 6(6):1629-1636. PubMed ID: 34638136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
    Sigmund AM; Denlinger N; Huang Y; Bond D; Voorhees T; Bajwa A; Elder P; Brammer JE; Saad A; Penza S; Vasu S; de Lima M; Jaglowski S; Kittai AS
    Transplant Cell Ther; 2022 Jun; 28(6):342.e1-342.e5. PubMed ID: 35248778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
    Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
    Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
    Zhou LH; Feng YQ; Hu YX; Huang H
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.
    Geng H; Jia S; Zhang Y; Li J; Yang Q; Zeng L; Zong X; Lu Y; Lu S; Zhou J; Li C; Wu D
    Front Immunol; 2023; 14():1219167. PubMed ID: 37671152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
    Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
    Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Boonlerd P; Tantiworawit A; Norasetthada L; Chai-Adisaksopha C; Punnachet T; Hantrakun N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Rattarittamrong E
    Ann Med; 2023; 55(2):2261109. PubMed ID: 37748107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
    Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
    [No Abstract]   [Full Text] [Related]  

  • 17. Zanubrutinib-lenalidomide-rituximab (ZR
    Wang Y; Xu J; Li P; Xu Y; Xue H; Liu P
    Ann Hematol; 2024 Feb; 103(2):499-510. PubMed ID: 37957370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
    Kong D; Ping N; Gao X; Zou R; Wang P; Wu D; Jin Z; Qu C
    Front Immunol; 2023; 14():1200748. PubMed ID: 37292195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
    Shen QD; Wang L; Zhu HY; Liang JH; Xia Y; Wu JZ; Fan L; Li JY; Xu W
    J Cancer; 2021; 12(1):163-169. PubMed ID: 33391412
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy and survival analysis of DICE regimen for 97 patients with relapsed or refractory Non-Hodgkin's lymphoma].
    Ping LY; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ying ZT; Liu WP; Zhang C; Deng LJ; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):790-794. PubMed ID: 27719723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.